After purchasing this CME Certification, you will receive a PDF download in your email containing the article and the evaluation. If you do not receive it, please check your spam box or contact kristy@acro.org.

The article, “Current Practices in, Reimbursement Opinions About, and Clinical Indications of Adaptive Radiation Therapy: Results From the American College of Radiation Oncology Survey” has been approved for .75 AMA PRA Category 1 credit(s). ^TM 

Target Audience:
Physicians (M.D. and D.O.) needing credit for relicensure or initial licensure.

Learning Objectives:

• Understand the current practices around billing for Adaptive Radiation Therapy (ART) and opinions of the community about appropriate reimbursement.
• Explain the current clinical utilization patterns for ART.
• Apply understanding of the current landscape to participate in discussions on the development of appropriate ART billing guidelines and possibly a separate ART billing code.
  

Date Credit Expires: 11/17/2027

Faculty Disclosure Information:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Miami-Dade County Medical Association and the American College of Radiation Oncology. The Miami-Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians.

The Miami-Dade County Medical Association designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

None of the planners or faculty of this activity had any financial relationships to disclose except for Paul Wallner who was an employee for Genesiscare USA (relationship has ended), a consultant for Health Management Associates, and an advisory board member for Nanocan Therapeutices, Inc. and Christopher Jahraus who is a consultant for RADformation, has other financial/material support from Klarity (Expert Witness) (relationship has ended), is a stock owner/investor in the privately held company Fuse Oncology, and was an advisory board member with Elekta (relationship has ended). All of the financial relationships identified for these planners and faculty have been mitigated.

Questions:
If you have any questions, please contact Kristy Williford.